CONMED (NYSE:CNMD) Releases FY 2025 Earnings Guidance

CONMED (NYSE:CNMD) updated its FY 2025 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 4.480-4.530 for the period, compared to the consensus estimate of 4.500. The company issued revenue guidance of $1.4 billion-$1.4 billion, compared to the consensus revenue estimate of $1.4 billion.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on CNMD. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of CONMED in a research note on Wednesday, October 8th. Piper Sandler decreased their price objective on CONMED from $68.00 to $55.00 and set an “overweight” rating on the stock in a report on Thursday, November 6th. JPMorgan Chase & Co. dropped their target price on shares of CONMED from $58.00 to $52.00 and set a “neutral” rating for the company in a report on Thursday, November 6th. Bank of America decreased their price target on shares of CONMED from $65.00 to $52.00 and set a “neutral” rating on the stock in a research note on Monday, December 8th. Finally, Wells Fargo & Company lowered their price target on shares of CONMED from $57.00 to $47.00 and set an “equal weight” rating on the stock in a research report on Thursday, November 6th. One equities research analyst has rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $53.67.

CONMED Stock Up 1.3%

NYSE CNMD opened at $40.17 on Friday. The company has a quick ratio of 0.95, a current ratio of 2.10 and a debt-to-equity ratio of 0.85. CONMED has a 52 week low of $38.32 and a 52 week high of $74.70. The business’s fifty day simple moving average is $43.15 and its 200-day simple moving average is $48.54. The firm has a market cap of $1.24 billion, a PE ratio of 19.60, a P/E/G ratio of 2.63 and a beta of 0.98.

CONMED (NYSE:CNMD) last released its quarterly earnings data on Wednesday, November 5th. The company reported $1.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.05 by $0.03. The firm had revenue of $337.93 million during the quarter, compared to analysts’ expectations of $334.76 million. CONMED had a net margin of 4.75% and a return on equity of 14.22%. CONMED’s revenue was up 6.7% compared to the same quarter last year. During the same period last year, the business earned $1.05 earnings per share. CONMED has set its FY 2025 guidance at 4.480-4.530 EPS. As a group, equities analysts anticipate that CONMED will post 4.35 earnings per share for the current year.

Institutional Investors Weigh In On CONMED

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CNMD. Public Sector Pension Investment Board lifted its stake in shares of CONMED by 7.7% in the 2nd quarter. Public Sector Pension Investment Board now owns 105,513 shares of the company’s stock valued at $5,495,000 after purchasing an additional 7,530 shares during the last quarter. Victory Capital Management Inc. raised its holdings in CONMED by 144.0% in the 3rd quarter. Victory Capital Management Inc. now owns 38,952 shares of the company’s stock valued at $1,832,000 after buying an additional 22,989 shares during the period. Dimensional Fund Advisors LP lifted its position in CONMED by 19.8% in the third quarter. Dimensional Fund Advisors LP now owns 1,296,776 shares of the company’s stock valued at $60,984,000 after buying an additional 214,126 shares during the last quarter. Natixis Advisors LLC lifted its position in CONMED by 48.2% in the third quarter. Natixis Advisors LLC now owns 174,810 shares of the company’s stock valued at $8,221,000 after buying an additional 56,876 shares during the last quarter. Finally, Russell Investments Group Ltd. boosted its stake in CONMED by 17.0% during the third quarter. Russell Investments Group Ltd. now owns 26,305 shares of the company’s stock worth $1,237,000 after buying an additional 3,821 shares during the period.

About CONMED

CONMED Corporation (NYSE: CNMD) is a global medical technology company headquartered in Utica, New York. Founded in 1970, CONMED develops, manufactures and markets a broad portfolio of surgical devices and accessories for minimally invasive procedures. The company’s product line supports surgeons and healthcare providers in specialties including orthopedics, general surgery, gastroenterology and gynecology.

CONMED operates two principal segments: Orthopedics, and Visualization & Energy.